Adults with asthma treated with add-on Omalizumab report lower dyspnea in activities of daily living

J. Oliveira (Londrina, Brazil), D. Rugila (Londrina, Brazil), J. Silva (Londrina, Brazil), V. Puzzi (Londrina, Brazil), F. Pitta (Londrina, Brazil), A. Cerci Neto (Londrina, Brazil), F. Soares (Londrina, Brazil), K. Furlanetto (Londrina, Brazil)

Source: Virtual Congress 2021 – Respiratory physiotherapy: e-health, activities of daily living and measurement properties of instruments

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Oliveira (Londrina, Brazil), D. Rugila (Londrina, Brazil), J. Silva (Londrina, Brazil), V. Puzzi (Londrina, Brazil), F. Pitta (Londrina, Brazil), A. Cerci Neto (Londrina, Brazil), F. Soares (Londrina, Brazil), K. Furlanetto (Londrina, Brazil). Adults with asthma treated with add-on Omalizumab report lower dyspnea in activities of daily living. 764

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of the relationship between the activity of daily living and dyspnoea in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 182s
Year: 2005

Quality of life of patients with asthma exacerbations treated with high doses of inhaled corticosteroids
Source: Eur Respir J 2002; 20: Suppl. 38, 114s
Year: 2002

A comparison of arm exercise capacity and activities of daily living between well-controlled asthma patients with and without severe fatigue during daily life
Source: Virtual Congress 2021 – Peripheral muscle function, exercise capacity and functional status in respiratory disease
Year: 2021


Tiotropium Respimat® add-on therapy in children with symptomatic asthma
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015


Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma
Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019
Year: 2020



Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006

Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


LATE-BREAKING ABSTRACT: Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma
Source: International Congress 2016 – Living with asthma around the globe
Year: 2016


Intermittent therapy with budesonide/formoterol in children with moderate asthma.
Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities
Year: 2017


Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016


Reduction in percent of days with asthma symptoms and activity limitation in young asthmatic children treated with Montelukast
Source: Eur Respir J 2001; 18: Suppl. 33, 290s
Year: 2001

Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012


Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Efficacy of montelukast in Indian patients having chronic persistent asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 372s
Year: 2003

Comparison of physical activity level, activities of daily living, and depression between the patients with asthma and bronchiectasis
Source: International Congress 2017 – Assessing pulmonary and extra-pulmonary function in chronic disease
Year: 2017

Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007